CorVent Medical announced that it received CE mark approval for its Respond-19 ventilator and is preparing to launch it in Europe.
Santa Clara, Calif.-based CorVent’s Respond-19 ventilator allows hospitals to treat more patients suffering from acute respiratory distress syndrome (ARDS). The system received FDA emergency use authorization (EUA) for primary critical care use in December 2020 amid the COVID-19 pandemic. CorVent expects full FDA clearance sometime this year.
Respond-19 offers flexible expansion of critical care ventilation and provides invasive and non-invasive respiratory support at a lower cost of ownership without traditional requirements for costly service or maintenance plans, CorVent said in a news release.
“The Respond-19 ventilator equips healthcare providers with a highly responsive fleet of ICU-quality ventilators. With a streamlined interface that can be deployed at moment’s notice, the Respond-19 ventilator allows clinicians to quickly meet the clinically demanding needs in a dynamic critical care setting, which was further exasperated by the pandemic,” Germany-based Thoraxklinik-Heidelberg University Hospital medical director Dr. Felix Herth said in the release. “The system’s advanced antiviral protection makes the Respond-19 ventilator an invaluable resource for limiting viral spread, protecting physicians and staff.”
In addition to CE mark approval, CorVent announced that it expanded its senior management team through the addition of Travis Murphy as its new CFO.
Murphy, a more than 30-year veteran of startups and growth-stage companies, primarily in medtech, offers know-how in day-to-day operating management, long-term strategic planning, fundraising and leading successful exits. His previous role before joining CoreVent was CFO at Ativa Medical.
“A hospital’s ventilation needs have shifted in recent years; they require flexibility to respond to changes in demand without the high cost of ongoing ownership. Today’s systems must meet the rigorous mechanical ventilation requirements of the ICU but also be easy to use and deployed rapidly to expand critical care capacity when time is limited,” CorVent CEO Richard S. Walsh said. “Our experienced team has made meaningful inroads into the respiratory market with the Respond-19 ventilator in a short time and the market’s response has been very positive. Bringing Travis Murphy on as our company’s CFO will be invaluable to expanding our commercialization efforts.”